Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Micallef

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Pageof 7